Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors

A compound of Formula I:

• wherein:
• R1 is an unsubstituted group selected from C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10cycloalkyl, C3-C10heterocycloalkyl, C3-C10cycloalkylC1-C6alkyl-, C3-C10heterocycloalkylC1-C6alkyl-, C6-C10arylC1-C6alkyl-, C5-C10heteroarylC1-C6alkyl-, C(O)Ra, ORa, NHRa, N(Ra)2, C(O)NH2, C(O)NHRa, C(O)N(Ra)2, NHC(O)Ra, N(Ra)C(O)Ra, NHC(O)NHRa, N(Ra)C(O)NHRa, NHC(O)N(Ra)2, N(Ra)C(O)N(Ra)2, NHSO2Ra, N(Ra)SO2Ra, NHSO2NHRa, N(Ra)SO2NHRa, NHSO2N(Ra)2, N(Ra)SO2N(Ra)2, SO2Ra, SO2NH2, SO2NHRa, and SO2N(Ra)2;
• or
• R1 is a group selected from C3-C10cycloalkyl, C3-C10heterocycloalkyl, C3-C10cycloalkylC1-C6alkyl-, C3-C10heterocycloalkylC1-C6alkyl-, C6-C10arylC1-C6alkyl- and C5-C10heteroarylC1-C6alkyl- which is substituted with one or more group(s) selected from halogen and alkoxy;
• or
• R1 is a branched or linear C1-C6alkyl group substituted with one or more group(s) selected from halogen, OH, NH2, CN, C3-C10cycloalkyl, C3-C10heterocycloalkyl optionally substituted with an oxo group, C6-C10aryl, C5-C10heteroaryl, C(O)Ra, ORa, NHRa, N(Ra)2, C(O)NH2, C(O)NHRa, C(O)N(Ra)2, NHC(O)Ra, N(Ra)C(O)Ra, NHC(O)NHRa, N(Ra)C(O)NHRa, NHC(O)N(Ra)2, N(Ra)C(O)N(Ra)2, NHSO2Ra, N(Ra)SO2Ra, NHSO2NHRa, N(Ra)SO2NHRa, NHSO2N(Ra)2, N(Ra)SO2N(Ra)2, SO2Ra, SO2NH2, SO2NHRa, and SO2N(Ra)2;
• each Ra is independently an unsubstituted group selected from C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10cycloalkyl, C3-C10heterocycloalkyl, C3-C10cycloalkylC1-C6alkyl-, C3-C10heterocycloalkylC1-C6alkyl-, C6-C10aryl, C5-C10heteroaryl, C6-C10arylC1-C6alkyl-, and C5-C10heteroarylC1-C6alkyl-;
• or
• Ra is independently a group selected from C1-C6alkyl, C3-C10cycloalkyl, C3-C10heterocycloalkyl, C3-C10cycloalkylC1-C6alkyl-, C3-C10heterocycloalkylC1-C6alkyl-, C6-C10aryl, C5-C10heteroaryl, C6-C10 arylC1-C6alkyl-, and C5-C10heteroarylC1-C6alkyl- which is substituted with one or more group(s) selected from halogen, alkyl and alkoxy;
• R2 is H, NH2, CN or a group selected from C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10cycloalkyl, C3-C10heterocycloalkyl, C6-C10aryl, C5-C10heteroaryl, C(O)Ra, ORa, SRa, NHRa, N(Ra)2, C(O)NH2, C(O)NHRa, C(O)N(Ra)2, NHC(O)Ra, SO2Ra, SO2NHRa, SO2N(Ra)2, NHSO2Ra, N(Ra)SO2Ra, NHSO2NHRa, N(Ra)SO2NHRa, NHSO2N(Ra)2, and N(Ra)SO2N(Ra)2;
• R3 and R6 are each independently H, halogen, NH2, CN or a group selected from C1-C6alkyl, C(O)Ra, ORa, NHRa, N(Ra)2, C(O)NH2, C(O)NHRa, C(O)N(Ra)2, and NHC(O)Ra;
• and
• one of R4 and R5 is H, halogen, NH2, CN or a group selected from C1-C6alkyl, C(O)Ra, NH2, NHRa, N(Ra)2, C(O)NH2, C(O)NHRa, C(O)N(Ra)2, and NHC(O)Ra;
• and the other of R4 and R5 is a group of Formula II:
• wherein:
• R7 and R10 are each independently H, halogen, CN, or a group selected from C1-C6alkyl, C3-C6cycloalkyl, OC1-C6alkyl, OC3-C6cycloalkyl, SC1-C6alkyl, SC3-C6cycloalkyl, NHC1-C6alkyl, NHC3-C6cycloalkyl, N(C1-C6alkyl)2, NHC(O)C1-C6alkyl and NHC(O)C3-C6cycloalkyl;
• R8 is halogen, CN, or a group selected from C1-C6alkyl, C3-C6cycloalkyl, OC1-C6alkyl, OC3-C6cycloalkyl, SC1-C6alkyl, SC3-C6cycloalkyl, NHC1-C6alkyl, NHC3-C6cycloalkyl, N(C1-C6alkyl)2, NHC(O)C1-C6alkyl and NHC(O)C3-C6cycloalkyl;
• R9 is a C1-C3alkyl or C3-C5cycloalkyl group;
• and
• X1, X2, and X3 are each selected from a nitrogen or carbon atom, wherein when X1, X2, or X3 is a nitrogen atom, then the R7, R8, or R10 attached thereto is absent, provided that at least two of X1, X2, and X3 are carbon atoms;
• wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl in the definitions of R2, R3, R4, R5, R6, R7, R8, R9 and R10 are independently optionally substituted with one or more substituents selected from halogen, OH, NH2, CN, C1-C6alkyl, C1-C6alkoxy, C3-C10heterocycloalkyl and C6-C10aryl;
• or a pharmaceutically acceptable salt thereof.